Tempus, a Chicago-based healthcare technology company, collaborated with Geisinger on the solution.

These findings are especially important, the authors explained, because the number of elderly patients on OACs continues to rise. 

The study’s authors tracked data from more than 2,800 patients with HFrEF, sharing their findings in JAMA Cardiology.

Researchers believe they have broken new ground that could make a significant impact on the treatment of genetic heart disease.

Officials confirmed, however, that they still believe the vaccine is safe and effective.  

STEMI mortality remains a primary concern among healthcare providers, and a new study in the American Journal of Cardiology suggests that long-term outcomes are much better if the patient undergoes primary PCI. 

The guidance, an update to a similar document from 2005, was published in Circulation: Cardiovascular Quality and Outcomes.

Rather than a binary choice—atherectomy or lithotripsy—the market for treating severely calcified lesions seems likely to evolve into a mixture of both technologies. 

“There’s no evidence that a mask mandate has worked,” the Stanford fellow and former White House advisor said during a recent panel discussion.